No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study

BACKGROUND: Currently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing an unprecedented pandemic. However, there is no specific antiviral therapy for coronavirus disease 2019 (COVID-19). We conducted a clinical trial to compare the effectiveness of three ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yin-Qiu, Tang, Sheng-Quan, Xu, Xiao-Lei, Zeng, Yan-Ming, He, Xiao-Qing, Li, Yao, Harypursat, Vijay, Lu, Yan-Qiu, Wan, Yan, Zhang, Lu, Sun, Qiang-Zhong, Sun, Nan-Nan, Wang, Gui-Xue, Yang, Zhong-Ping, Chen, Yao-Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378850/
https://www.ncbi.nlm.nih.gov/pubmed/32765274
http://dx.doi.org/10.3389/fphar.2020.01071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378850/
https://www.ncbi.nlm.nih.gov/pubmed/32765274
http://dx.doi.org/10.3389/fphar.2020.01071

Ejemplares similares